longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Curium to acquire Lantheus in all-cash deal worth up to $8bn

Pharmaceutical Technology
Aug 4, 2026 at 08:43 AM

Curium has agreed to acquire Nasdaq-listed Lantheus in an all-cash deal valued at up to $8 billion. Under the terms, Curium will buy all outstanding shares for $102.50 per share, plus contingent value rights potentially adding $12.00 per share by 2030, bringing the total potential consideration to $114.50 per share. This represents a significant premium over Lantheus' recent stock prices. The transaction, unanimously approved by Lantheus' board, is expected to close in the first half of 2027, subject to regulatory and shareholder approvals.

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Login to unlock221characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Lantheus

Lantheus

LNTH.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI